Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

Inclusion Criteria:

1. Myelodysplastic syndrome (MDS) diagnosed according to the 2022 InternationalConsensus Classification of Myeloid Neoplasms and Acute Leukemia (2022ICC) criteria,acute myeloid leukemia (AML) with TP53 mutation (unrestricted remission status),minimal residual disease (MRD) monitored by flow cytometry within 2 months afterreceiving the first allogeneic hematopoietic stem cell transplantation Negativepatients

2. Male or female, aged 12-65 years

3. Karnofsky score >60, estimated survival time >3 months

4. No history of severe graft-versus-host disease (GVHD), uncontrolled GVHD, or severesystemic organ dysfunction:

5. Absolute neutrophil count (ANC) greater than 0.5×109/L

6. Creatinine < 1.5mg/dL

7. Cardiac ejection index >55%

8. Signed informed consent.

Exclusion Criteria:

1. severe cardiac, renal, or liver dysfunction

2. combined with other malignant tumors requiring treatment

3. inability to understand or adhere to the study protocol due to clinical symptoms ofbrain dysfunction or severe mental illness

4. patients who are unable to complete the necessary treatment plan and follow-upobservation

5. patients with severe acute anaphylaxis

6. clinically uncontrolled severe life-threatening infections

7. patients enrolled in other clinical trials

8. other reasons considered by the investigator to be inappropriate for clinical trialparticipants.